VIMTALABS Vimta Labs Q4 FY26 results (Jan–Mar 2026) and concall
Vimta Labs delivered a strong Q4 and FY26, showcasing robust revenue and EBITDA growth driven by pharmaceutical and food testing. The company successfully launched its biologics contract research services, with infrastructure ready for execution. Despite facing geopolitical uncertainties and competitive pressures, Vimta maintains a healthy financial position and is focused on sustaining margins and driving future growth through its core services and new ventures.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 16.0%, net profit up 16.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 85 | 90 | 94 | 98 | 102 +20% | 99 +10% | 109 +16% |
| EBITDA | 30 | 33 | 33 | 34 | 34 +13% | 34 +3% | 39 +18% |
| Net profit | 15 | 22 | 18 | 19 | 20 +33% | 18 −18% | 21 +17% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
